Cutting Edge: A Dual TLR2 and TLR7 Ligand Induces Highly Potent Humoral and Cell-Mediated Immune Responses
Cutting Edge: A Dual TLR2 and TLR7 Ligand Induces Highly Potent Humoral and Cell-Mediated Immune Responses
复制标题
DOI：
10.4049/jimmunol.1602131
复制
发表时间：
2017-06-01
影响因子：
4.4
通讯作者：
Paul, Stephane
中科院分区：
文献类型：
--
作者：
Gutjahr, Alice;Papagno, Laura;Paul, Stephane
TLR激动剂目前正在开发和测试作为佐剂在各种制剂中，以优化疫苗的免疫原性和功效。本研究的目的是评估一种新型化合物的免疫刺激特性，该化合物包含设计用于刺激TLR 2和TLR 7的共价连接的部分。这种TLR 2/TLR 7双重激动剂在体外诱导树突状细胞成熟，并引发大量溶细胞和高度多功能效应CD 8（+）T细胞，并安全地增强体内纳米颗粒Ag的免疫原性，在小鼠中引发具有平衡TH 1/TH 2特征的体液应答。总的来说，这些数据揭示了具有通过TLR介导的协同活性的嵌合佐剂的潜在效用。
TLR agonists are currently being developed and tested as adjuvants in various formulations to optimize the immunogenicity and efficacy of vaccines. The aim of this study was to evaluate the immunostimulatory properties of a novel compound incorporating covalently linked moieties designed to stimulate both TLR2 and TLR7. This dual TLR2/TLR7 agonist induced the maturation of dendritic cells and primed substantial populations of cytolytic and highly polyfunctional effector CD8(+) T cells in vitro, and safely potentiated the immunogenic properties of a nanoparticulate Ag in vivo, eliciting humoral responses with a balanced TH1/TH2 profile in mice. Collectively, these data reveal the potential utility of chimeric adjuvants with synergistic activities mediated via TLRs.